TRCT
ETON icon

Tower Research Capital (TRC)’s Eton Pharmaceutcials ETON Stock Holding History

Tower Research Capital (TRC)’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.5K Sell
1,156
-1,838
-61% -$32.1K ﹤0.01% 3214
2025
Q4 		$50.6K Buy
2,994
+2,023
+208% +$35.6K ﹤0.01% 2404
2025
Q3 		$21.1K Sell
971
-1,587
-62% -$26.3K ﹤0.01% 3263
2025
Q2 		$36.5K Sell
2,558
-413
-14% -$6.53K ﹤0.01% 3238
2025
Q1 		$38.6K Sell
2,971
-3,462
-54% -$52.3K ﹤0.01% 2414
2024
Q4 		$85.7K Buy
+6,433
New +$65.2K ﹤0.01% 2234
2024
Q3 		– Sell
-3,638
Closed -$12K – 5780
2024
Q2 		$12K Sell
3,638
-3,955
-52% -$13.8K ﹤0.01% 4056
2024
Q1 		$28.5K Buy
7,593
+3,531
+87% +$15.4K ﹤0.01% 2695
2023
Q4 		$17.8K Buy
4,062
+2,890
+247% +$11.6K ﹤0.01% 3730
2023
Q3 		$4.89K Sell
1,172
-3,202
-73% -$12.4K ﹤0.01% 4798
2023
Q2 		$15.3K Buy
4,374
+973
+29% +$3.58K ﹤0.01% 3640
2023
Q1 		$13K Sell
3,401
-246
-7% -$897 ﹤0.01% 3959
2022
Q4 		$10K Sell
3,647
-2,053
-36% -$5.52K ﹤0.01% 3987
2022
Q3 		$12K Buy
5,700
+3,634
+176% +$9.05K ﹤0.01% 4334
2022
Q2 		$5K Buy
2,066
+728
+54% +$2.44K ﹤0.01% 5043
2022
Q1 		$6K Buy
+1,338
New +$5.26K ﹤0.01% 4870
2021
Q4 		– Sell
-4,382
Closed -$22K – 6246
2021
Q3 		$22K Buy
+4,382
New +$22.8K ﹤0.01% 3625
2021
Q2 		– Sell
-2,764
Closed -$20K – 5561
2021
Q1 		$20K Buy
2,764
+456
+20% +$3.89K ﹤0.01% 3876
2020
Q4 		$19K Sell
2,308
-11,628
-83% -$89.7K ﹤0.01% 3899
2020
Q3 		$110K Sell
13,936
-1,950
-12% -$13.3K ﹤0.01% 3081
2020
Q2 		$87K Buy
+15,886
New +$78.9K ﹤0.01% 2584
2020
Q1 		– Sell
-22
Closed – – 3265
2019
Q4 		$0 Sell
22
-1,285
-98% -$7.94K ﹤0.01% 3754
2019
Q3 		$8K Sell
1,307
-1,832
-58% -$11.7K ﹤0.01% 3070
2019
Q2 		$25K Buy
3,139
+1,728
+122% +$13.4K ﹤0.01% 2025
2019
Q1 		$11K Buy
1,411
+1,252
+787% +$8.7K ﹤0.01% 2629
2018
Q4 		$1K Buy
+159
New +$975 ﹤0.01% 3575

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Tower Research Capital (TRC)'s ETON Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Eton Pharmaceutcials (ETON) stake by 61% in Q1 2026, selling an estimated $32.1K and leaving 1,156 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3214.

Tower Research Capital (TRC) first reported a position in ETON in Q4 2018 and has held it in 26 quarters since. The position peaked at $110K in Q3 2020. 116 funds tracked by Wall St. Rank hold ETON as of Q1 2026.

  • Tower Research Capital (TRC) held 1,156 shares of Eton Pharmaceutcials worth $28.5K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,838 Eton Pharmaceutcials shares in Q1 2026, an estimated $32.1K.
  • Eton Pharmaceutcials made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3214 holding.
  • Tower Research Capital (TRC) first reported a position in Eton Pharmaceutcials in Q4 2018 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Eton Pharmaceutcials position peaked at $110K in Q3 2020.
  • 116 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.